Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)
2018年6月5日 更新者：Bristol-Myers Squibb
A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.
調査の概要
研究の種類
介入
入学 (実際)
20976
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35209
- Cardiovascular Associates, Pc
-
Birmingham、Alabama、アメリカ、35235
- Alabama Internal Medicine Pc
-
Birmingham、Alabama、アメリカ、35235
- Birmingham Heart Clinic P.C.
-
Huntsville、Alabama、アメリカ、35801
- Heart Center, Inc.
-
Mobile、Alabama、アメリカ、36608
- Mobile Heart Specialists, PC
-
Mobile、Alabama、アメリカ、36617
- Clara V. Massey, Md
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99508
- Alaska Heart Institute
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006
- Internal Medicine Physicians Associates, P.C.
-
Tucson、Arizona、アメリカ、85723
- Southern Arizona VA Health Care System
-
Tucson、Arizona、アメリカ、85710
- Southwest Heart
-
Tucson、Arizona、アメリカ、85745
- Pima Research Foundation
-
-
Arkansas
-
Hot Springs、Arkansas、アメリカ、71913
- Dr. Rajesh Shroff
-
Little Rock、Arkansas、アメリカ、72204
- Mary K. Richards, Md Pa
-
-
California
-
Anaheim、California、アメリカ、92801
- Advanced Clinical Reserach Institute
-
Beverly Hills、California、アメリカ、90210
- Act/Cardiovascular Research Institute
-
Carmichael、California、アメリカ、95608
- Capitol Interventional Cardiology
-
Escondido、California、アメリカ、92025
- Escondido Cardiology Associates, Inc.
-
Healdsburg、California、アメリカ、95448
- William D. Bowden, D.O.
-
La Mesa、California、アメリカ、91942
- La Mesa Cardiac Center, A Medical Group
-
Los Angeles、California、アメリカ、90073
- VA Greater Los Angeles Healthcare System
-
Mission Viejo、California、アメリカ、92691
- Coastal Cardiology
-
Oceanside、California、アメリカ、92056
- Kenneth W. Carr Md
-
Palm Springs、California、アメリカ、92262
- Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group
-
Rancho Mirage、California、アメリカ、92270
- Desert Cardiology Consultants Medical Group, Inc
-
Sacramento、California、アメリカ、95821
- Northern California Research
-
Sacramento、California、アメリカ、95825
- Sacramento Heart And Vascular Medical Associates
-
Sacramento、California、アメリカ、95819
- Regional Cardiolody Associates
-
Santa Barbara、California、アメリカ、93105
- Arrhythmia Consultants Of The Central Coast Medical Group
-
Santa Rosa、California、アメリカ、95403
- Northern California Medical Associates
-
Vista、California、アメリカ、92083
- Progressive Clinical Research
-
Walnut Creek、California、アメリカ、94598
- Cardivasclular Consultants Medical Group
-
Wildomar、California、アメリカ、92595
- Shiva Heart Center Medical Group
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80910
- Electrophysiology Associates, Pc
-
Denver、Colorado、アメリカ、80220
- Denver VA Medical Center
-
Denver、Colorado、アメリカ、80218
- Aurora Denver Cardiology Associates, P.C.
-
Golden、Colorado、アメリカ、80401
- New West Physicians Clinical Research
-
Littleton、Colorado、アメリカ、80120
- South Denver Cardiology Associates PC
-
-
Connecticut
-
Bridgeport、Connecticut、アメリカ、06610
- Bridgeport Hospital
-
Bridgeport、Connecticut、アメリカ、06606
- Connecticut Clinical Research, Llc
-
Guilford、Connecticut、アメリカ、06437
- Cardiology Associates Of New Haven,Pc
-
Norwich、Connecticut、アメリカ、06360
- William W Backus Hospital
-
Norwich、Connecticut、アメリカ、06360
- The William W. Backus Hospital
-
Stamford、Connecticut、アメリカ、06905
- Stamford Therapeutics Consortium
-
Waterbury、Connecticut、アメリカ、06708
- Chase Medical Research, LLC
-
-
Delaware
-
Newark、Delaware、アメリカ、19713
- Alfieri Cardiology
-
-
District of Columbia
-
Washington、District of Columbia、アメリカ、20422
- Washington VA Medical Center
-
Washington、District of Columbia、アメリカ、20037
- George Washington University Medical Faculty Associates
-
-
Florida
-
Atlantis、Florida、アメリカ、33462
- Medical Specialist Of The Palm Beach
-
Aventura、Florida、アメリカ、33180
- Miami International Cardiology Consultants
-
Boca Raton、Florida、アメリカ、33431
- David Charles Mishkel, Md, Pa
-
Clearwater、Florida、アメリカ、33756
- The Heart & Vascular Institute Of Florida
-
Clearwater、Florida、アメリカ、33756
- The Heart And Vascular Institute Of Florida
-
Davie、Florida、アメリカ、33324
- Cardiovascular Specialist Of South Florida
-
Daytona Beach、Florida、アメリカ、32114
- Daytona Heart Group
-
Fort Lauderdale、Florida、アメリカ、33316
- Broward General Medical Center
-
Fort Lauderdale、Florida、アメリカ、33308
- Cardiology Associates Of Fort Lauderdale, P.A.
-
Fort Myers、Florida、アメリカ、33907
- Florida Heart Associates
-
Gainesville、Florida、アメリカ、32605
- Florida Research Network, LLC
-
Hollywood、Florida、アメリカ、33021
- Healthworx
-
Hollywood、Florida、アメリカ、33021
- Luis Tami, Md
-
Inverness、Florida、アメリカ、34452
- Nature Coast Clinical Research
-
Jacksonville、Florida、アメリカ、32216
- Jacksonville Center for Clinical Research
-
Jacksonville、Florida、アメリカ、32216
- Jacksonville Cardiovascular Center
-
Jacksonville、Florida、アメリカ、32258
- Jacksonville Heart Center, Pa
-
Jacksonville、Florida、アメリカ、32204
- St. Vincent'S Ambulatory Care, Inc
-
Jacksonville、Florida、アメリカ、32207
- Jacksonville Heart Center, Pa
-
Jacksonville、Florida、アメリカ、32216
- St. Luke'S Cardiology
-
Jacksonville Beach、Florida、アメリカ、32250
- Jacksonville Heart Center, P.A.
-
Jupiter、Florida、アメリカ、33458
- Cvms Research Institute, Llc
-
Jupiter、Florida、アメリカ、33458
- Ricardo Bedoya, M.D.
-
Melbourne、Florida、アメリカ、32901
- Melbourne Internal Medicine Associates
-
Miami、Florida、アメリカ、33137
- Miami International Cardiology Consultants
-
Miami、Florida、アメリカ、33137-3732
- Miami International Cardiology Consultants
-
Naples、Florida、アメリカ、34119
- Physicians Regional Medical Group
-
Orlando、Florida、アメリカ、32803
- Florida Heart Group
-
Oviedo、Florida、アメリカ、32765
- Alpha Medical Research
-
Pensacola、Florida、アメリカ、32501
- Cardiology Consultants
-
Saint Petersburg、Florida、アメリカ、33709
- The Heart And Vascular Institute Of Florida
-
Sarasota、Florida、アメリカ、34239
- Heart & Vascular Center Research, Inc.
-
Sarasota、Florida、アメリカ、34232
- Niranjan Seshadri, Md
-
Vero Beach、Florida、アメリカ、32960
- Research, Inc.
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30342
- Cardiovascular Specialits, Pc
-
Augusta、Georgia、アメリカ、30901
- Augusta Cardiology Clinic, P.C.
-
Columbus、Georgia、アメリカ、31909
- Columbus Cardiology Associates Pc
-
Columbus、Georgia、アメリカ、31909
- Columbus Cardiology Associates,Pc
-
Covington、Georgia、アメリカ、30014
- Georgia Heart Specialists, L.L.C.
-
Decatur、Georgia、アメリカ、30030
- Atlanta Institute For Medical Research, Inc
-
Gainesville、Georgia、アメリカ、30501
- Northeast Georgia Heart Center, PC
-
Marietta、Georgia、アメリカ、30060
- Wellstar Cardiovascular Medicine, Pc
-
-
Illinois
-
Aurora、Illinois、アメリカ、60504
- Fox Valley Clinical Research Center, LLC
-
Chicago、Illinois、アメリカ、60611
- Nmff
-
Gurnee、Illinois、アメリカ、60031
- Clinical Investigation Specialists, Inc
-
Maywood、Illinois、アメリカ、60153
- Loyola University Medical Center
-
Normal、Illinois、アメリカ、61761
- Illinois Heart & Lung Research Center, Sc
-
North Chicago、Illinois、アメリカ、60064
- Cpt. James A Lovell Federal Health Care Center
-
-
Indiana
-
Anderson、Indiana、アメリカ、46011
- Community Clinical Research Center
-
Bloomington、Indiana、アメリカ、47403
- Premier Healthcare, Llc
-
Elkhart、Indiana、アメリカ、46514
- Elkhart Clinic, LLC
-
Fort Wayne、Indiana、アメリカ、46804
- Lutheran Medical Group, Llc
-
Fort Wayne、Indiana、アメリカ、46805
- Fort Wayne Cardiology
-
Indianapolis、Indiana、アメリカ、46290
- The Care Group, Llc
-
Indianapolis、Indiana、アメリカ、46290
- The Care Group, Llc.
-
Indianapolis、Indiana、アメリカ、46237
- St Francis Medical Group - Indiana Heart Physicians
-
Michigan City、Indiana、アメリカ、46360
- Dali, Sammi
-
South Bend、Indiana、アメリカ、46601
- Cardiology Associates, Inc.
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic PC
-
-
Kansas
-
Overland Park、Kansas、アメリカ、66209
- Midwest Cardiology Associates , P.C.
-
-
Kentucky
-
Elizabethtown、Kentucky、アメリカ、42701
- Central Cardiology Assoc.
-
Lexington、Kentucky、アメリカ、40504
- New Lexington Clinic, P.S.C.
-
Louisville、Kentucky、アメリカ、40205
- Norton Cardiovascular Associates
-
Louisville、Kentucky、アメリカ、40202
- VA Medical Center
-
Owensboro、Kentucky、アメリカ、42303
- Owensboro Heart & Vascular
-
-
Louisiana
-
Alexandria、Louisiana、アメリカ、71301
- Alexandria Cardiology Clinic
-
Houma、Louisiana、アメリカ、70360
- Cardiovascular Institute of the South
-
Lacombe、Louisiana、アメリカ、70445
- Smith, Patel & Amkieh, Llc
-
Lake Charles、Louisiana、アメリカ、70601
- Imperial Calcasieu Medical Group, Llp
-
Marrero、Louisiana、アメリカ、70072
- Cardiology Center, Llc
-
Shreveport、Louisiana、アメリカ、71105
- Cardiology Associates
-
Slidell、Louisiana、アメリカ、70458
- Louisiana Heart Center
-
Slidell、Louisiana、アメリカ、70458
- Medical Research Inst, Inc
-
Slidell、Louisiana、アメリカ、70458
- Medical Research Institute, Inc
-
Ventura、Louisiana、アメリカ、93003
- Ventura Cardio. Cond. Med. Group, Inc.
-
-
Maine
-
Lewiston、Maine、アメリカ、04240
- Central Maine Heart & Vascular Institute
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21224
- Johns Hopkins Bayview Medical Center
-
Baltimore、Maryland、アメリカ、21237
- Franklin Square Hospital
-
Baltimore、Maryland、アメリカ、21208
- Midatlantic Cardiovascular Associates, Pa
-
Baltimore、Maryland、アメリカ、21237
- Midatlantic Cardiovascular Associates, Pa
-
Baltimore、Maryland、アメリカ、21204
- Midatlantic Cardiovascular Associates, P.A.
-
Baltimore、Maryland、アメリカ、21218
- Midatlantic Cardiovascular Associates, P.A.
-
Baltimore、Maryland、アメリカ、21224-2735
- Johns Hopkins Bayview Medical Center
-
Baltimore、Maryland、アメリカ、21237
- Midatlantic Cardiovascular Associates, P.A.
-
Bel Air、Maryland、アメリカ、21014
- Midatlantic Cardiovascular Associates, Pa
-
Columbia、Maryland、アメリカ、21044
- Cardiovascular Specialists Of Central Maryland, P.A.
-
Reisterstown、Maryland、アメリカ、21136
- Clinical Associates Research
-
Westminster、Maryland、アメリカ、21157
- Midatlantic Cardiovascular Associates, Pa
-
-
Massachusetts
-
Billerica、Massachusetts、アメリカ、01821
- Burlington Medical Associates
-
Boston、Massachusetts、アメリカ、02135
- Caritas St. Elizabeth's Medical Center
-
Burlington、Massachusetts、アメリカ、01805
- Lahey Clinic Medical Center
-
Fall River、Massachusetts、アメリカ、02720
- Neccr Internal Medicine & Cardiology Associates,Llc
-
Haverhill、Massachusetts、アメリカ、01830
- Pentucket Medical Associates
-
Haverhill、Massachusetts、アメリカ、01830-6278
- Pentucket Medical Associates
-
Natick、Massachusetts、アメリカ、01760
- Charles River Medical Associates
-
-
Michigan
-
Alpena、Michigan、アメリカ、49707
- Great Lakes Heart Center Of Alpena
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
Lansing、Michigan、アメリカ、48910
- Thoracic And Cardiovascular Healthcare Foundation
-
Livonia、Michigan、アメリカ、48154
- Advanced Cardiovascular Health Specialists, Pc
-
Petoskey、Michigan、アメリカ、49770
- Michigan Heart And Vascular Specialists
-
Royal Oak、Michigan、アメリカ、48073
- William Beaumont Hospital
-
Ypsilanti、Michigan、アメリカ、48197
- Michigan Heart, P.C.
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota
-
Minneapolis、Minnesota、アメリカ、55417
- Minneapolis VA Medical Center
-
Robbinsdale、Minnesota、アメリカ、55422
- North Memorial Health Care
-
-
Mississippi
-
Olive Branch、Mississippi、アメリカ、38654
- Olive Branch Family Medical Center
-
Tupelo、Mississippi、アメリカ、38801
- Tupelo Neurology Clinic, Pa
-
-
Missouri
-
Columbia、Missouri、アメリカ、65212
- University of Missouri
-
Kansas City、Missouri、アメリカ、64108
- Truman Medical Center
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Lipid and Diabetes Research Center
-
-
Nebraska
-
Grand Island、Nebraska、アメリカ、68803
- Internal Medical Associates Of Grand Island, P.C
-
Grand Island、Nebraska、アメリカ、68803-4311
- Internal Medical Associates Of Grand Island, P.C
-
Hastings、Nebraska、アメリカ、68901
- Nebraska Heart Institute
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89106
- VA Southern Nevada Healthcare System
-
-
New Jersey
-
Berlin、New Jersey、アメリカ、08009
- Comprehensive Clinical Research
-
Elmer、New Jersey、アメリカ、08318
- Cardiovascular Associates Of The Delware Valley, P.A.
-
Haddon Heights、New Jersey、アメリカ、08035
- Cardiovascular Associates Of The Delaware Valley, P.A.
-
Princeton、New Jersey、アメリカ、08540
- Princeton Medical Institute
-
Sewell、New Jersey、アメリカ、08080
- Cardio Assoc Of Del Val, P.A.
-
South Plainfield、New Jersey、アメリカ、07080
- Central New Jersey Cardiology
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87012
- Abq Health Partners, Llc
-
Albuquerque、New Mexico、アメリカ、87131-0001
- University Of New Mexico/University Hospital
-
Albuquerque、New Mexico、アメリカ、87131
- University Of New Mexico/University Hospital
-
-
New York
-
Albany、New York、アメリカ、12205
- Albany Associates In Cardiology
-
Albany、New York、アメリカ、12205
- Albany Assoc. In Cardiology
-
Binghamton、New York、アメリカ、13905
- Cardiology Associates, Pc
-
Buffalo、New York、アメリカ、14215
- Buffalo Heart Group, LLP
-
Buffalo、New York、アメリカ、14215-1145
- Buffalo Heart Group, LLP
-
Buffalo、New York、アメリカ、14215
- Bruce L. Platt Md, Pc
-
Buffalo、New York、アメリカ、14215
- Bruce L. Platt, Md
-
East Syracuse、New York、アメリカ、13057
- Heart Care Center, P.C.
-
Huntington、New York、アメリカ、11743
- Huntington Hospital
-
Liverpool、New York、アメリカ、13088
- SJH Cardiology Associates
-
Mineola、New York、アメリカ、11501
- Long Island Heart Associates
-
Saratoga Springs、New York、アメリカ、12866
- Saratoga Cardiology Associates, Pc
-
Williamsville、New York、アメリカ、14221
- Office Of Dr. Kozinn
-
Williamsville、New York、アメリカ、14221
- Suburban Cardiology
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28803
- Asheville Cardiology Associates
-
Burlington、North Carolina、アメリカ、27215
- Kernodle Clinic, Inc.
-
High Point、North Carolina、アメリカ、27262
- Carolina Cardiology Associates, Pa
-
Pinehurst、North Carolina、アメリカ、28374
- Pinehurst Medical Center, Inc
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58103
- Lillestol Research LLC
-
-
Ohio
-
Akron、Ohio、アメリカ、44304
- Akron Cardiology Consultants
-
Bucyrus、Ohio、アメリカ、44820
- Christopher M. Johnson, D.O.
-
Bucyrus、Ohio、アメリカ、OHIO
- Christopher M. Johnson, D.O.
-
Canal Fulton、Ohio、アメリカ、44614
- Community Health Care, Inc.
-
Canton、Ohio、アメリカ、44710
- Cardiology Associates
-
Cincinnati、Ohio、アメリカ、45219
- The Carl & Edyth Lindner Center For R&E At The Christ Hosp
-
Toledo、Ohio、アメリカ、43608
- Toledo Cardiology Consultants
-
Wadsworth、Ohio、アメリカ、44281
- Family Practice Center of Wadsworth, Inc.
-
-
Oklahoma
-
Muskogee、Oklahoma、アメリカ、74401
- Jack C. Va Medical Center
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、アメリカ、73112
- Plaza Medical Group, Pc
-
Oklahoma City、Oklahoma、アメリカ、73103
- COR Clinical Research, LLC
-
Oklahoma City、Oklahoma、アメリカ、73135
- South Oklahoma Heart Research
-
Oklahoma City、Oklahoma、アメリカ、73120
- Oklahoma Heart Hospital Physicians
-
Oklahoma City、Oklahoma、アメリカ、73139
- Eminence Research, LLC
-
Tulsa、Oklahoma、アメリカ、74136
- Castlerock Clinical Research Consultants, Llc
-
-
Oregon
-
Bend、Oregon、アメリカ、97701
- St. Charles Health System, Inc.
-
Bend、Oregon、アメリカ、97701
- St. Charles Health System, Inc
-
Eugene、Oregon、アメリカ、97401
- Oregon Medical Group - Clinical Research
-
Hillsboro、Oregon、アメリカ、97123
- Hillsboro Cardiology Pc
-
Medford、Oregon、アメリカ、97504
- Rogue Valley Physicians - Clinical Research Group
-
-
Pennsylvania
-
Abington、Pennsylvania、アメリカ、19001
- Abington Medical Specialists
-
Altoona、Pennsylvania、アメリカ、16602
- Blair Medical Associates, Inc.
-
Camp Hill、Pennsylvania、アメリカ、17011
- Heritage Cardiology Assoc.
-
Doylestown、Pennsylvania、アメリカ、18901
- Central Bucks Cardiology
-
Erie、Pennsylvania、アメリカ、16509
- Internal Medicine And Lipid Mgmt.
-
Harrisburg、Pennsylvania、アメリカ、17112
- Kandra, Fierer, Kuskin Associates
-
Hatfield、Pennsylvania、アメリカ、19440
- Pivotal Clinical Research, Llc
-
Jersey Shore、Pennsylvania、アメリカ、17740
- Lycoming Internal Medicine Inc.
-
Sayre、Pennsylvania、アメリカ、18840
- Guthrie Medical Group, P.C.
-
Sayre、Pennsylvania、アメリカ、18840
- Guthrie Clinic Ltd.
-
Uniontown、Pennsylvania、アメリカ、15401
- Preferred Primary Care Physicians
-
West Chester、Pennsylvania、アメリカ、19380
- West Chester Cardiology, Pc
-
Yardley、Pennsylvania、アメリカ、19067
- Cardiology Consultants of Philadelphia
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital
-
-
South Carolina
-
Anderson、South Carolina、アメリカ、29621
- Southeastern Research Associates, Inc
-
Beaufort、South Carolina、アメリカ、29906
- Lowcountry Medical Group, Llc
-
Beaufort、South Carolina、アメリカ、29906
- Lowcountry Medical Group
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Columbia、South Carolina、アメリカ、29203
- Columbia Heart Clinic
-
Greenville、South Carolina、アメリカ、29607
- Upstate Cardiology
-
Greer、South Carolina、アメリカ、29650
- Internal Medicine Of Greer
-
Orangeburg、South Carolina、アメリカ、29118
- Palmetto Nephrology Pa
-
Spartanburg、South Carolina、アメリカ、29303
- S. Carolina Pharmaceutical Research
-
-
South Dakota
-
Pierre、South Dakota、アメリカ、57501
- Avera Medical Associates Clinic
-
-
Tennessee
-
Bristol、Tennessee、アメリカ、37620
- Holston Medical Group
-
Kingsport、Tennessee、アメリカ、37660
- Holston Medical Group
-
Knoxville、Tennessee、アメリカ、37920
- Volunteer Research Group
-
Knoxville、Tennessee、アメリカ、37916
- Knoxville Heart Group
-
Knoxville、Tennessee、アメリカ、37920-1502
- Volunteer Research Group
-
Tullahoma、Tennessee、アメリカ、37388
- Tennessee Center for Clinical Trials
-
-
Texas
-
Amarillo、Texas、アメリカ、79106
- Amarillo Heart Clinical Research Institute Inc.
-
Corsicana、Texas、アメリカ、75110
- Corsicana Medical Research, PLLC
-
Dallas、Texas、アメリカ、75226
- Soltero Cardiovascular Research Center
-
Dallas、Texas、アメリカ、75230
- HeartPlace
-
Fort Worth、Texas、アメリカ、76104
- Heart Center of North Texas
-
Houston、Texas、アメリカ、77030
- The Methodist Hospital
-
Houston、Texas、アメリカ、77030
- The University of Texas MD Anderson Cancer Center
-
Houston、Texas、アメリカ、77030
- Center For Atrial Fibrillation
-
Houston、Texas、アメリカ、77030
- The Methodist Hospital Neurology Institute
-
Houston、Texas、アメリカ、77065
- Northwest Houston Cardiology, Pa
-
Houston、Texas、アメリカ、77070
- Northwest Houston Cardiology, Pa
-
Houston、Texas、アメリカ、77074
- Francisco R. Maislos
-
Houston、Texas、アメリカ、77090
- Woodlands North Houston Heart Center
-
Humble、Texas、アメリカ、77338
- Regional Medical Center And Diagnostic Clinics
-
Lackland Air Force Base、Texas、アメリカ、78236
- Wilford Hall Medical Center
-
Lackland Air Force Base、Texas、アメリカ、78236-9908
- Wilford Hall Medical Center
-
Longview、Texas、アメリカ、75605
- DCOL Center for Clinical Research
-
McKinney、Texas、アメリカ、75069
- North Dallas Research Associates
-
Plano、Texas、アメリカ、75093
- North Texas Medical Research
-
Plano、Texas、アメリカ、75024
- Legacy Heart Center
-
San Antonio、Texas、アメリカ、78229
- Covenant Clinical Research, Pa
-
San Antonio、Texas、アメリカ、78217
- Bhs Specialty Network, Inc
-
San Antonio、Texas、アメリカ、78229
- Star Clinical Trails
-
Seguin、Texas、アメリカ、78155
- Edward Balli, Md, Pa
-
Tomball、Texas、アメリカ、77375
- Northwest Heart Center
-
Tyler、Texas、アメリカ、75701
- Tyler Cardiovascular Consultants
-
Tyler、Texas、アメリカ、75708
- University of Texas Health Science Center at Tyler
-
Tyler、Texas、アメリカ、75708
- The Univ. Of Texas Health Science Ctr. At Tyler
-
-
Utah
-
Layton、Utah、アメリカ、84041
- Utah Cardiology P.C
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23510
- Sentara York Clinical Research
-
Richmond、Virginia、アメリカ、23220
- Medical Research Initiatives
-
Roanoke、Virginia、アメリカ、24014
- Roanoke Heart Institute, Plc
-
Virginia Beach、Virginia、アメリカ、23454
- Cardiovascular Associates
-
-
Washington
-
Burien、Washington、アメリカ、98166
- Daniel W. Gottlieb, Md, Ps
-
Burien、Washington、アメリカ、98166
- Daniel William Gottlieb, Md
-
Spokane、Washington、アメリカ、99202
- Rockwood Clinic Research Cent.
-
Walla Walla、Washington、アメリカ、99362
- Walla Walla Clinic
-
-
West Virginia
-
Lewisburg、West Virginia、アメリカ、24901
- Lynn N. Smith, Md
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54301
- Cardiology Associates Of Green Bay Ltd-Bellin Hospital
-
Madison、Wisconsin、アメリカ、53715
- St. Mary's Hospital
-
Madison、Wisconsin、アメリカ、53715
- St.Mary's Hospital
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Health Care
-
Waukesha、Wisconsin、アメリカ、53188
- Cardiology Assc. Of Waukesha
-
-
-
-
-
Buenos Aires、アルゼンチン、1119
- Local Institution
-
Buenos Aires、アルゼンチン、C1280AEB
- Local Institution
-
Buenos Aires、アルゼンチン、1181
- Local Institution
-
Buenos Aires、アルゼンチン、C1426ANZ
- Local Institution
-
Buenos Aires、アルゼンチン、1280
- Local Institution
-
Cordoba、アルゼンチン、5000
- Local Institution
-
Cordoba、アルゼンチン、X5000EPU
- Local Institution
-
Cordoba、アルゼンチン、X5008KKF
- Local Institution
-
Cordoba、アルゼンチン、X5003DCE
- Local Institution
-
Salta、アルゼンチン、4400
- Local Institution
-
Santa Fe、アルゼンチン、3000
- Local Institution
-
Tucuman、アルゼンチン、T4000NIL
- Local Institution
-
-
Buenos Aires
-
Adrogue、Buenos Aires、アルゼンチン、1846
- Local Institution
-
Bahia Blanca、Buenos Aires、アルゼンチン、B8000FTD
- Local Institution
-
Ciudad Autonoma、Buenos Aires、アルゼンチン、CP1425A WC
- Local Institution
-
Ciudad Autonoma、Buenos Aires、アルゼンチン、1128AAD
- Local Institution
-
Ciudad Autonoma、Buenos Aires、アルゼンチン、1128
- Local Institution
-
Ciudad Autonoma、Buenos Aires、アルゼンチン、1426 EGR
- Local Institution
-
Ciudad Autonoma、Buenos Aires、アルゼンチン、C1426 EGR
- Local Institution
-
Ciudad Autonoma、Buenos Aires、アルゼンチン、CP1425AWC
- Local Institution
-
Ciudad Autonoma De、Buenos Aires、アルゼンチン、1180
- Local Institution
-
Ciudad Autonoma De Buenos Aire、Buenos Aires、アルゼンチン、CI094AAD
- Local Institution
-
Coronel Suarez、Buenos Aires、アルゼンチン、B7540GHD
- Local Institution
-
Haedo、Buenos Aires、アルゼンチン、B1706AJU
- Local Institution
-
Junin、Buenos Aires、アルゼンチン、6000
- Local Institution
-
La Plata、Buenos Aires、アルゼンチン、1900
- Local Institution
-
La Plata、Buenos Aires、アルゼンチン、B1900AXI
- Local Institution
-
La Plata、Buenos Aires、アルゼンチン、1902
- Local Institution
-
Mar Del Plata、Buenos Aires、アルゼンチン、7600
- Local Institution
-
Merlo、Buenos Aires、アルゼンチン、B1722COV
- Local Institution
-
Merlo、Buenos Aires、アルゼンチン、1722
- Local Institution
-
Olivos、Buenos Aires、アルゼンチン、1602
- Local Institution
-
Quilmes、Buenos Aires、アルゼンチン、1878
- Local Institution
-
Ramos Mejia、Buenos Aires、アルゼンチン、B1704ESN
- Local Institution
-
Ramos Mejia、Buenos Aires、アルゼンチン、B1704ETD
- Local Institution
-
Ramos Mejia、Buenos Aires、アルゼンチン、1706
- Local Institution
-
San Justo、Buenos Aires、アルゼンチン、1754
- Local Institution
-
San Martin、Buenos Aires、アルゼンチン、1650
- Local Institution
-
San Nicolas、Buenos Aires、アルゼンチン、2900
- Local Institution
-
Zarate、Buenos Aires、アルゼンチン、2800
- Local Institution
-
Zarate、Buenos Aires、アルゼンチン、B2800DGH
- Local Institution
-
-
Provincia DE Cordoba
-
Cordoba、Provincia DE Cordoba、アルゼンチン、5000
- Local Institution
-
-
RIO Negro
-
Cipolletti、RIO Negro、アルゼンチン、8324
- Local Institution
-
-
Santa FE
-
Rosario、Santa FE、アルゼンチン、2000
- Local Institution
-
Rosario、Santa FE、アルゼンチン、S2000CVB
- Local Institution
-
Rosario、Santa FE、アルゼンチン、S2001ODA
- Local Institution
-
-
Santa Fe
-
Rosario、Santa Fe、アルゼンチン、S2000CVD
- Local Institution
-
Rosario、Santa Fe、アルゼンチン、S2000 CVD
- Local Institution
-
-
Tucuman
-
San Miquel De Tucuman、Tucuman、アルゼンチン、4000
- Local Institution
-
-
-
-
-
Antrim、イギリス、BT41 2RL
- Local Institution
-
Blackpool、イギリス、FY3 8NR
- Local Institution
-
Glasgow、イギリス、G21 3UW
- Local Institution
-
-
Aberdeenshire
-
Aberdeen、Aberdeenshire、イギリス、AB25 2ZN
- Local Institution
-
Glasgow、Aberdeenshire、イギリス、G11 6NT
- Local Institution
-
-
Antrim
-
Belfast、Antrim、イギリス、BT14 6AB
- Local Institution
-
-
Armagh
-
Craigavon、Armagh、イギリス、BT63 5QQ
- Local Institution
-
-
Cambridgeshire
-
Cambridge、Cambridgeshire、イギリス、CB2 2QQ
- Local Institution
-
Peterborough、Cambridgeshire、イギリス、PE2 5GP
- Local Institution
-
-
Derbyshire
-
Chesterfield、Derbyshire、イギリス、S44 5BL
- Local Institution
-
Chesterfield、Derbyshire、イギリス、S40 4TF
- Local Institution
-
-
Dorset
-
Bournemouth、Dorset、イギリス、BH7 7DW
- Local Institution
-
-
Dumbartonshire
-
Glasgow、Dumbartonshire、イギリス、G11 6NT
- Local Institution
-
-
EAST Sussex
-
Chichester、EAST Sussex、イギリス、PO19 6SE
- Local Institution
-
-
Essex
-
Colchester、Essex、イギリス、C03 4LN
- Local Institution
-
Romford、Essex、イギリス、RH7 0AG
- Local Institution
-
-
Greater London
-
Denmark Hill、Greater London、イギリス、SE5 9RS
- Local Institution
-
London、Greater London、イギリス、SW17 0RE
- Local Institution
-
-
Gwent
-
Newport、Gwent、イギリス、NP20 2UB
- Local Institution
-
-
Hertfordshire
-
Barnet、Hertfordshire、イギリス、EN5 3DJ
- Local Institution
-
-
MID Glamorgan
-
Cardiff、MID Glamorgan、イギリス、CF14 4XW
- Local Institution
-
Llandough、MID Glamorgan、イギリス、CF64 2XX
- Local Institution
-
-
Middlesex
-
Harrow、Middlesex、イギリス、HA1 3UJ
- Local Institution
-
-
Nottinghamshire
-
Nottingham、Nottinghamshire、イギリス、NG5 1PB
- Local Institution
-
Worksop、Nottinghamshire、イギリス、S81 OBD
- Local Institution
-
-
Renfrewshire
-
Paisley、Renfrewshire、イギリス、PA2 9PN
- Local Institution
-
-
South Yorkshire
-
Barnsley、South Yorkshire、イギリス、S75 2EP
- Local Institution
-
Doncaster、South Yorkshire、イギリス、DN2 5LT
- Local Institution
-
-
Stirlingshire
-
Stirling、Stirlingshire、イギリス、FK8 2AU
- Local Institution
-
-
Strathclyde
-
Glasgow、Strathclyde、イギリス、G51 4TF
- Local Institution
-
-
Suffolk
-
Bury St Edmunds、Suffolk、イギリス、IP31 2HD
- Local Institution
-
Bury St Edmunds、Suffolk、イギリス、IP33 2QZ
- Local Institution
-
Bury St. Edmunds、Suffolk、イギリス、IP30 9QU
- Local Institution
-
Ipswich、Suffolk、イギリス、IP14 2PU
- Local Institution
-
Ipswich、Suffolk、イギリス、IP7 5DN
- Local Institution
-
-
Tyne and Wear
-
Newcastle Upon Tyne、Tyne and Wear、イギリス、NE1 4LP
- Local Institution
-
-
WEST Glamorgan
-
Swansea、WEST Glamorgan、イギリス、SA6 6NL
- Local Institution
-
-
WEST Lothian
-
Livingston、WEST Lothian、イギリス、EH54 6PP
- Local Institution
-
-
WEST Midlands
-
Birmingham、WEST Midlands、イギリス、B18 7QH
- Local Institution
-
-
Wiltshire
-
Westbury、Wiltshire、イギリス、BA 13 3JD
- Local Institution
-
Westbury、Wiltshire、イギリス、BA13 3JD
- Local Institution
-
-
Yorkshire
-
York、Yorkshire、イギリス、YO31 8HE
- Local Institution
-
York、Yorkshire、イギリス、YO31 HE
- Local Institution
-
-
-
-
-
Afula、イスラエル、18101
- Local Institution
-
Ashkelon、イスラエル、78306
- Local Institution
-
Givatayim、イスラエル、53583
- Local Institution
-
Hadera、イスラエル、38100
- Local Institution
-
Haifa、イスラエル、31096
- Local Institution
-
Haifa、イスラエル、34362
- Local Institution
-
Holon、イスラエル、58100
- Local Institution
-
Jerusalem、イスラエル、91120
- Local Institution
-
Jerusalem、イスラエル、91240
- Local Institution
-
Kfar-Saba、イスラエル、44281
- Local Institution
-
Nazareth、イスラエル、16100
- Local Institution
-
Nazareth、イスラエル、16000
- Local Institution
-
Petach-Tikva、イスラエル、49100
- Local Institution
-
Safed、イスラエル、13100
- Local Institution
-
Tel Aviv、イスラエル、64239
- Local Institution
-
-
-
-
-
Ascoli Piceno、イタリア、63100
- Local Institution
-
Campobasso、イタリア、86100
- Local Institution
-
Chieti、イタリア、66013
- Local Institution
-
Cremona、イタリア、26100
- Local Institution
-
Fidenza (Pr)、イタリア、43036
- Local Institution
-
Genova、イタリア、16132
- Local Institution
-
Isernia、イタリア、86170
- Local Institution
-
Livorno、イタリア、57100
- Local Institution
-
Milano、イタリア、20132
- Local Institution
-
Napoli、イタリア、80131
- Local Institution
-
Palermo、イタリア、90127
- Local Institution
-
Reggio Emilia、イタリア、42100
- Local Institution
-
Roma、イタリア、00168
- Local Institution
-
San Daniele De Friuli、イタリア、33038
- Local Institution
-
Torino、イタリア、10153
- Local Institution
-
Vittorio Veneto (Tv)、イタリア、31029
- Local Institution
-
-
Lucca
-
Lido Di Camaiore、Lucca、イタリア、55043
- Local Institution
-
-
-
-
-
Ahmedabad、インド、380014
- Local Institution
-
Annamalainagar、インド、608002
- Local Institution
-
Bangalore、インド、560052
- Local Institution
-
Chennai、インド、600006
- Local Institution
-
Hyderabad、インド、500001
- Local Institution
-
Hyderabad、インド、500044
- Local Institution
-
Indore、インド、452014
- Local Institution
-
Indore、インド、452001
- Local Institution
-
Kolkata、インド、700054
- Local Institution
-
Kottayam、インド、686016
- Local Institution
-
Lucknow、インド、226003
- Local Institution
-
Mumbai Naka、インド、422005
- Local Institution
-
Nashik、インド、422002
- Local Institution
-
New Delhi、インド、110025
- Local Institution
-
New Delhi、インド、110060
- Local Institution
-
New Delhi、インド、116025
- Local Institution
-
Pune、インド、411001
- Local Institution
-
Pune、インド、411004
- Local Institution
-
Thrissur、インド、680002
- Local Institution
-
Vijayawada、インド、520008
- Local Institution
-
-
Andhra Pradesh
-
Visakhapatnam、Andhra Pradesh、インド、530003
- Local Institution
-
-
Andhrapradesh
-
Visakhapatnam、Andhrapradesh、インド、530002
- Local Institution
-
-
Andra Pradesh
-
Hyderabad、Andra Pradesh、インド、500004
- Local Institution
-
-
Gujarat
-
Ahmedabad、Gujarat、インド、380060
- Local Institution
-
Vadodara、Gujarat、インド、390007
- Local Institution
-
-
Karnataka
-
Bangalore、Karnataka、インド、560054
- Local Institution
-
Bangalore、Karnataka、インド、5600034
- Local Institution
-
Bangalore、Karnataka、インド、560094
- Local Institution
-
Mysore、Karnataka、インド、570004
- Local Institution
-
-
Kerela
-
Calicut、Kerela、インド、673 004
- Local Institution
-
-
Maharashta
-
Pune、Maharashta、インド、411011
- Local Institution
-
-
Maharashtra
-
Nagpur、Maharashtra、インド、440010
- Local Institution
-
Nagpur、Maharashtra、インド、440012
- Local Institution
-
Pune、Maharashtra、インド、411001
- Local Institution
-
Pune、Maharashtra、インド、421006
- Local Institution
-
-
Punjab
-
Jalandhar、Punjab、インド、144008
- Local Institution
-
-
Rajasthan
-
Bikaner、Rajasthan、インド、334001
- Local Institution
-
Bikaner、Rajasthan、インド、334003
- Local Institution
-
-
Uttar Pradesh
-
Lucknow、Uttar Pradesh、インド、226003
- Local Institution
-
-
-
-
-
Chernivtsy、ウクライナ、58013
- Local Institution
-
Dnipropetrovsk、ウクライナ、49006
- Local Institution
-
Dnipropetrovsk、ウクライナ、49060
- Local Institution
-
Donetsk、ウクライナ、83045
- Local Institution
-
Donetsk、ウクライナ、83003
- Local Institution
-
Donetsk、ウクライナ、83114
- Local Institution
-
Ivano-Frankivsk、ウクライナ、76025
- Local Institution
-
Kharkiv、ウクライナ、61018
- Local Institution
-
Kharkiv、ウクライナ、61115
- Local Institution
-
Kharkov、ウクライナ、61039
- Local Institution
-
Kharkov、ウクライナ、61002
- Local Institution
-
Kharkov、ウクライナ、61178
- Local Institution
-
Kiev、ウクライナ、01032
- Local Institution
-
Kyiv、ウクライナ、03680
- Local Institution
-
Kyiv、ウクライナ、02091
- Local Institution
-
Kyiv、ウクライナ、03049
- Local Institution
-
Kyiv、ウクライナ、03115
- Local Institution
-
Kyiv、ウクライナ、04050
- Local Institution
-
Kyiv、ウクライナ、04107
- Local Institution
-
Kyiv、ウクライナ、01023
- Local Institution
-
Kyiv、ウクライナ、02660
- Local Institution
-
Kyiv、ウクライナ、01103
- Local Institution
-
Lugansk、ウクライナ、91011
- Local Institution
-
Lugansk、ウクライナ、91016
- Local Institution
-
Lutsk、ウクライナ、43024
- Local Institution
-
Lviv、ウクライナ、79013
- Local Institution
-
Lviv、ウクライナ、79015
- Local Institution
-
Mykolayiv、ウクライナ、54003
- Local Institution
-
Odessa、ウクライナ、65009
- Local Institution
-
Odessa、ウクライナ、65039
- Local Institution
-
Odessa、ウクライナ、65114
- Local Institution
-
Odessa、ウクライナ、65025
- Local Institution
-
Uzhgorod、ウクライナ、88000
- Local Institution
-
Vinnitsa、ウクライナ、21029
- Local Institution
-
Zaporozhye、ウクライナ、69035
- Local Institution
-
Zhytomyr、ウクライナ、10002
- Local Institution
-
-
-
-
-
Breda、オランダ、4818 CK
- Local Institution
-
Deventer、オランダ、7416 SE
- Local Institution
-
Eindhoven、オランダ、5623 EJ
- Local Institution
-
Eindhoven、オランダ、5623EJ
- Local Institution
-
Enschede、オランダ、7513 ER
- Local Institution
-
Hardenberg、オランダ、7772 SE
- Local Institution
-
Hilversum、オランダ、1213 XZ
- Local Institution
-
Nijmegen、オランダ、6525 GA
- Local Institution
-
Oss、オランダ、5342 BT
- Local Institution
-
Rotterdam、オランダ、3045 PM
- Local Institution
-
S-Hertogenbosch、オランダ、5211 NL
- Local Institution
-
Tiel、オランダ、4002 WP
- Local Institution
-
Utrecht、オランダ、3582 KE
- Local Institution
-
Velp、オランダ、6883 AZ
- Local Institution
-
-
-
-
New South Wales
-
Coffs Harbour、New South Wales、オーストラリア、2450
- Local Institution
-
Concord、New South Wales、オーストラリア、2139
- Local Institution
-
Gosford、New South Wales、オーストラリア、2250
- Local Institution
-
Kogarah、New South Wales、オーストラリア、2217
- Local Institution
-
Miranda、New South Wales、オーストラリア、2228
- Local Institution
-
-
Queensland
-
Auchenflower、Queensland、オーストラリア、4066
- Local Institution
-
Brisbane、Queensland、オーストラリア、4032
- Local Institution
-
Caboolture、Queensland、オーストラリア、4510
- Local Institution
-
Herston、Queensland、オーストラリア、4029
- Local Institution
-
Kippa Ring、Queensland、オーストラリア、4021
- Local Institution
-
Nambour、Queensland、オーストラリア、4560
- Local Institution
-
Sherwood、Queensland、オーストラリア、4075
- Local Institution
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、SA 5000
- Local Institution
-
Ashford、South Australia、オーストラリア、5035
- Local Institution
-
Bedford Park、South Australia、オーストラリア、5042
- Local Institution
-
Woodville、South Australia、オーストラリア、5011
- Local Institution
-
-
Victoria
-
Box Hill、Victoria、オーストラリア、3128
- Local Institution
-
Dandenong、Victoria、オーストラリア、3175
- Local Institution
-
Geelong、Victoria、オーストラリア、3220
- Local Institution
-
-
Western Australia
-
Fremantle、Western Australia、オーストラリア、6160
- Local Institution
-
Joondalup、Western Australia、オーストラリア、6027
- Local Institution
-
-
-
-
-
Graz、オーストリア、8036
- Local Institution
-
Oberpullendorf、オーストリア、7350
- Local Institution
-
Vienna、オーストリア、1160
- Local Institution
-
-
-
-
-
Quebec、カナダ、G1J 1Z6
- Local Institution
-
-
Alberta
-
Calgary、Alberta、カナダ、T2E 7C5
- Local Institution
-
Edmonton、Alberta、カナダ、T6G 2B7
- Local Institution
-
Edmonton、Alberta、カナダ、T5X 3N5
- Local Institution
-
Edmonton、Alberta、カナダ、TSA 4L8
- Local Institution
-
Edmonton、Alberta、カナダ、T56-3NJ
- Local Institution
-
-
British Columbia
-
Burnaby、British Columbia、カナダ、V5G 1T4
- Local Institution
-
Nanaimo、British Columbia、カナダ、V9R 3G9
- Local Institution
-
New Westminster、British Columbia、カナダ、V3L 3W4
- Local Institution
-
North Vancouver、British Columbia、カナダ、V7N 4M2
- Local Institution
-
Victoria、British Columbia、カナダ、V8R 4R2
- Local Institution
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R2V 4W3
- Local Institution
-
-
New Brunswick
-
Bathurst、New Brunswick、カナダ、E2A 4X7
- Local Institution
-
-
Newfoundland and Labrador
-
Mount Pearl、Newfoundland and Labrador、カナダ、A1N 1W7
- Local Institution
-
St Johns、Newfoundland and Labrador、カナダ、A1B 3V6
- Local Institution
-
St. John'S、Newfoundland and Labrador、カナダ、A1A 3R5
- Local Institution
-
St. John'S、Newfoundland and Labrador、カナダ、A1E 2C2
- Local Institution
-
-
Ontario
-
Brampton、Ontario、カナダ、L6Z 4N5
- Local Institution
-
Burlington、Ontario、カナダ、L7M 4Y1
- Local Institution
-
Cambridge、Ontario、カナダ、N1R 7R1
- Local Institution
-
Cambridge、Ontario、カナダ、N1R 6V6
- Local Institution
-
Hamilton、Ontario、カナダ、L8L 2X2
- Local Institution
-
London、Ontario、カナダ、N6G 2V2
- Local Institution
-
Mississauga、Ontario、カナダ、L5B 4A2
- Local Institution
-
Newmarket、Ontario、カナダ、L3Y 5G8
- Local Institution
-
Newmarket、Ontario、カナダ、L3Y 8C3
- Local Institution
-
Niagara Falls、Ontario、カナダ、L2E 7H1
- Local Institution
-
Niagara Falls、Ontario、カナダ、L2E7H1
- Local Institution
-
North Bay、Ontario、カナダ、P1B 2H3
- Local Institution
-
Oshawa、Ontario、カナダ、L1J 2J9
- Local Institution
-
Oshawa、Ontario、カナダ、L1J 2K1
- Local Institution
-
Ottawa、Ontario、カナダ、K1Y 4E9
- Local Institution
-
Ottawa、Ontario、カナダ、K1Y 4W7
- Local Institution
-
Sarnia、Ontario、カナダ、N7T 4X3
- Local Institution
-
Scarborough、Ontario、カナダ、M1B 5N1
- Local Institution
-
Sudbury、Ontario、カナダ、P3E 3B8
- Local Institution
-
Sudbury、Ontario、カナダ、P3C 5K7
- Local Institution
-
Sudbury、Ontario、カナダ、P3E 2N8
- Local Institution
-
Sudbury、Ontario、カナダ、P3C5K7
- Local Institution
-
Toronto、Ontario、カナダ、M9W 4L6
- Local Institution
-
Toronto、Ontario、カナダ、M5B 1W8
- Local Institution
-
Weston、Ontario、カナダ、M9N 1W4
- Local Institution
-
-
Prince Edward Island
-
Charlottetown、Prince Edward Island、カナダ、C1A 5Y9
- Local Institution
-
-
Quebec
-
Drummondville、Quebec、カナダ、J2B 7T1
- Local Institution
-
Greenfield Park、Quebec、カナダ、J4V 2G8
- Local Institution
-
Lachine、Quebec、カナダ、H8S 2E4
- Local Institution
-
Levis、Quebec、カナダ、G6V 4Z5
- Local Institution
-
Longueuil、Quebec、カナダ、J4K 1C8
- Local Institution
-
Longueuil、Quebec、カナダ、J4N 0C9
- Local Institution
-
Longueuil、Quebec、カナダ、J4N 1C2
- Local Institution
-
Montreal、Quebec、カナダ、H3T 1E2
- Local Institution
-
Montreal、Quebec、カナダ、H3A 1A1
- Local Institution
-
Montreal、Quebec、カナダ、H1T 1C8
- Local Institution
-
Montreal、Quebec、カナダ、H2W 1T8
- Local Institution
-
Montreal、Quebec、カナダ、W3R-153
- Local Institution
-
Pointe- Claire、Quebec、カナダ、H9R 3J1
- Local Institution
-
St-Lambert、Quebec、カナダ、J4P 2H4
- Local Institution
-
Ste-Foy、Quebec、カナダ、G1W 4R4
- Local Institution
-
-
Saskatchewan
-
Saskatoon、Saskatchewan、カナダ、S7L OY7
- Local Institution
-
-
-
-
-
Barranquilla、コロンビア
- Local Institution
-
Barranquilla、コロンビア、XXXXX
- Local Institution
-
Bogota、コロンビア
- Local Institution
-
Bogota、コロンビア、000
- Local Institution
-
Cali、コロンビア
- Local Institution
-
Medellin、コロンビア
- Local Institution
-
-
Antioquia
-
Medellin、Antioquia、コロンビア
- Local Institution
-
-
-
-
-
Singapore、シンガポール、168752
- Local Institution
-
-
-
-
-
Baden、スイス、5404
- Local Institution
-
Bern、スイス、3010
- Local Institution
-
-
-
-
-
Goteberg、スウェーデン、413 45
- Local Institution
-
Helsingborg、スウェーデン、251 87
- Local Institution
-
Linkoping、スウェーデン、581 85
- Local Institution
-
Lund、スウェーデン、222 21
- Local Institution
-
Orebro、スウェーデン、70185
- Local Institution
-
Orebro、スウェーデン、701 85
- Local Institution
-
Skelleftea、スウェーデン、931 86
- Local Institution
-
Stockholm、スウェーデン、141 86
- Local Institution
-
Stockholm、スウェーデン、171 76
- Local Institution
-
Stockholm、スウェーデン、111 57
- Local Institution
-
Stockholm、スウェーデン、118 83
- Local Institution
-
Stockholm、スウェーデン、111 35
- Local Institution
-
Uppsala、スウェーデン、751 85
- Local Institution
-
Vaxjo、スウェーデン、351 85
- Local Institution
-
-
-
-
-
Albacete、スペイン、02006
- Local Institution
-
Barcelona、スペイン、08035
- Local Institution
-
Barcelona、スペイン、08003
- Local Institution
-
Elda、スペイン、03600
- Local Institution
-
Figueres、スペイン、17600
- Local Institution
-
Gerona、スペイン、17007
- Local Institution
-
Las Palmas、スペイン、35010
- Local Institution
-
Madrid、スペイン、28006
- Local Institution
-
Madrid、スペイン、28046
- Local Institution
-
Madrid、スペイン、28040
- Local Institution
-
Palma De Mallorca、スペイン、07010
- Local Institution
-
San Sebastian De Los Reyes、スペイン、28703
- Local Institution
-
Tarragona、スペイン、43007
- Local Institution
-
Viladecans、スペイン、08840
- Local Institution
-
-
Alicante
-
San Juan、Alicante、スペイン、03550
- Local Institution
-
Torrevieja、Alicante、スペイン、03186
- Local Institution
-
-
Almeria
-
La Canada、Almeria、スペイン、04120
- Local Institution
-
-
Galicia
-
Lugo、Galicia、スペイン、27003
- Local Institution
-
-
-
-
-
Boskovice、チェコ、680 21
- Local Institution
-
Brno、チェコ、625 00
- Local Institution
-
Brno-Malomerice、チェコ、614 00
- Local Institution
-
Ivancice、チェコ、664 91
- Local Institution
-
Kladno、チェコ、272 59
- Local Institution
-
Litomysl、チェコ、570 14
- Local Institution
-
Mestec Kralove、チェコ、289 03
- Local Institution
-
Ostrava、チェコ、70852
- Local Institution
-
Prague 13、チェコ、158 00
- Local Institution
-
Prague 2、チェコ、128 08
- Local Institution
-
Pribram、チェコ、261 01
- Local Institution
-
Usti Nad Orlici、チェコ、562 18
- Local Institution
-
-
-
-
LOS Lagos
-
Osorno、LOS Lagos、チリ、5311089
- Local Institution
-
Osorno、LOS Lagos、チリ、5311523
- Local Institution
-
-
Metropolitana
-
Santiago、Metropolitana、チリ、7500520
- Local Institution
-
Santiago、Metropolitana、チリ、7500922
- Local Institution
-
Santiago、Metropolitana、チリ、8330074
- Local Institution
-
-
Region DE LA Araucania
-
Temuco、Region DE LA Araucania、チリ、4781176
- Local Institution
-
-
Region De La Araucania
-
Temuco、Region De La Araucania、チリ、4781156
- Local Institution
-
-
Valparaiso
-
Temuco、Valparaiso、チリ、4781173
- Local Institution
-
Vina Del Mar、Valparaiso、チリ、2570017
- Local Institution
-
-
-
-
-
Arhus C、デンマーク、8000
- Local Institution
-
Esbjerg、デンマーク、6700
- Local Institution
-
Frederiksberg、デンマーク、2000
- Local Institution
-
Frederikssund、デンマーク、3600
- Local Institution
-
Gentofte、デンマーク、2900
- Local Institution
-
Haderslev、デンマーク、6100
- Local Institution
-
Hellerup、デンマーク、2900
- Local Institution
-
Herlev、デンマーク、2730
- Local Institution
-
Herning、デンマーク、7400
- Local Institution
-
Hillerod、デンマーク、3400
- Local Institution
-
Hvidovre、デンマーク、2650
- Local Institution
-
Kobenhavn、デンマーク、2100
- Local Institution
-
Kolding、デンマーク、6000
- Local Institution
-
Odense、デンマーク、5000
- Local Institution
-
Silkeborg、デンマーク、8600
- Local Institution
-
Slagelse、デンマーク、4200
- Local Institution
-
Svendborg、デンマーク、5700
- Local Institution
-
-
-
-
-
Aachen、ドイツ、52074
- Local Institution
-
Bad Krozingen、ドイツ、79189
- Local Institution
-
Bad Neustadt/ Salle、ドイツ、97616
- Local Institution
-
Bad Oeynhausen、ドイツ、32545
- Local Institution
-
Berlin、ドイツ、13353
- Local Institution
-
Berlin、ドイツ、14050
- Local Institution
-
Berlin、ドイツ、10787
- Local Institution
-
Berlin、ドイツ、10789
- Local Institution
-
Berlin、ドイツ、12043
- Local Institution
-
Berlin-Kopenick、ドイツ、12559
- Local Institution
-
Betzdorf、ドイツ、57518
- Local Institution
-
Bochum、ドイツ、44791
- Local Institution
-
Bochum、ドイツ、44789
- Local Institution
-
Bonn、ドイツ、53127
- Local Institution
-
Coburg、ドイツ、96450
- Local Institution
-
Dillingen、ドイツ、66763
- Local Institution
-
Dresden、ドイツ、01099
- Local Institution
-
Duisburg、ドイツ、47139
- Local Institution
-
Essen、ドイツ、45122
- Local Institution
-
Frankfurt Am Main、ドイツ、60594
- Local Institution
-
Gottingen、ドイツ、37075
- Local Institution
-
Halle/Saale、ドイツ、06120
- Local Institution
-
Hannover、ドイツ、30625
- Local Institution
-
Heidelberg、ドイツ、69120
- Local Institution
-
Heidelberg、ドイツ、69115
- Local Institution
-
Kassel、ドイツ、34121
- Local Institution
-
Lahr、ドイツ、77933
- Local Institution
-
Ludwigshafen、ドイツ、67063
- Local Institution
-
Ludwigshafen、ドイツ、67073
- Local Institution
-
Mannheim、ドイツ、68167
- Local Institution
-
Marburg、ドイツ、35043
- Local Institution
-
Munchen、ドイツ、81675
- Local Institution
-
Munchen、ドイツ、80636
- Local Institution
-
Munchen、ドイツ、81545
- Local Institution
-
Osnabruck、ドイツ、49076
- Local Institution
-
Regensburg、ドイツ、93053
- Local Institution
-
Riesa、ドイツ、D-01587
- Local Institution
-
Rostiock、ドイツ、18057
- Local Institution
-
Trier、ドイツ、54292
- Local Institution
-
Waren、ドイツ、17192
- Local Institution
-
Witten、ドイツ、58455
- Local Institution
-
Wolmirstedt、ドイツ、39326
- Local Institution
-
Worms、ドイツ、67550
- Local Institution
-
-
-
-
-
Alesund、ノルウェー、6003
- Local Institution
-
Bergen、ノルウェー、5021
- Local Institution
-
Bergen、ノルウェー、N-5021
- Local Institution
-
Elverum、ノルウェー、2408
- Local Institution
-
Flekkefjord、ノルウェー、4400
- Local Institution
-
Nesttun、ノルウェー、5221
- Local Institution
-
Oslo、ノルウェー、0407
- Local Institution
-
Skien、ノルウェー、3710
- Local Institution
-
Stavanger、ノルウェー、4064
- Local Institution
-
Straume、ノルウェー、5353
- Local Institution
-
Tonsberg、ノルウェー、3116
- Local Institution
-
Tromso、ノルウェー、9038
- Local Institution
-
-
-
-
-
Budapest、ハンガリー、1125
- Local Institution
-
Budapest、ハンガリー、1023
- Local Institution
-
Budapest、ハンガリー、1032
- Local Institution
-
Budapest、ハンガリー、1096
- Local Institution
-
Budapest、ハンガリー、1085
- Local Institution
-
Debrecen、ハンガリー、4032
- Local Institution
-
Dunaujvaros、ハンガリー、2400
- Local Institution
-
Gyor、ハンガリー、9023
- Local Institution
-
Gyula、ハンガリー、5700
- Local Institution
-
Hodmezovasarhely、ハンガリー、6800
- Local Institution
-
Komarom、ハンガリー、2921
- Local Institution
-
Mosonmagyarovar、ハンガリー、9200
- Local Institution
-
Oroshaza、ハンガリー、5900
- Local Institution
-
Pecs、ハンガリー、7624
- Local Institution
-
Siofok、ハンガリー、8600
- Local Institution
-
Siofok、ハンガリー、8601
- Local Institution
-
Sopron、ハンガリー、9400
- Local Institution
-
Szentes、ハンガリー、6600
- Local Institution
-
Zalaegerszeg、ハンガリー、8900
- Local Institution
-
-
-
-
-
Manila、フィリピン、1000
- Local Institution
-
Manila、フィリピン、1008
- Local Institution
-
Naga City、フィリピン、4400
- Local Institution
-
Pasig City、フィリピン、1600
- Local Institution
-
Quezon、フィリピン、1100
- Local Institution
-
Quezon City、フィリピン、1102
- Local Institution
-
San Juan、フィリピン、1100
- Local Institution
-
-
Ilocos Norte
-
Laoag City、Ilocos Norte、フィリピン、2900
- Local Institution
-
-
-
-
-
Helsinki、フィンランド、00280
- Local Institution
-
Helsinki、フィンランド、FI-00280
- Local Institution
-
Hus、フィンランド、00029
- Local Institution
-
Jyvaskyla、フィンランド、40100
- Local Institution
-
Kemi、フィンランド、94100
- Local Institution
-
Oulu、フィンランド、90100
- Local Institution
-
Pori、フィンランド、28120
- Local Institution
-
Tampere、フィンランド、33100
- Local Institution
-
-
-
-
-
Amiens Cedex 1、フランス、80054
- Local Institution
-
Bordeaux Cedex、フランス、33075
- Local Institution
-
Brest、フランス、29609
- Local Institution
-
Grenoble Cedex 09、フランス、38043
- Local Institution
-
La Seyne Sur Mer、フランス、83500
- Local Institution
-
Paris Cedex 18、フランス、75018
- Local Institution
-
Six Fours Les Plages、フランス、83140
- Local Institution
-
-
-
-
-
Rio De Janeiro、ブラジル、20551
- Local Institution
-
Rio De Janeiro、ブラジル、20551-030
- Local Institution
-
Rio De Janeiro、ブラジル、22251-030
- Local Institution
-
Rio De Janeiro、ブラジル、22251
- Local Institution
-
Sao Paulo、ブラジル、01323-010
- Local Institution
-
Sao Paulo、ブラジル、01323
- Local Institution
-
Sao Paulo、ブラジル、04012
- Local Institution
-
Sao Paulo、ブラジル、04024-002
- Local Institution
-
Sao Paulo、ブラジル、04038
- Local Institution
-
Sao Paulo、ブラジル、01221-900
- Local Institution
-
Sao Paulo、ブラジル、01221
- Local Institution
-
Sao Paulo、ブラジル、01322-001
- Local Institution
-
Sao Paulo、ブラジル、01322
- Local Institution
-
Sao Paulo、ブラジル、01323-001
- Local Institution
-
Sao Paulo、ブラジル、04012-180
- Local Institution
-
Sao Paulo、ブラジル、04024
- Local Institution
-
Sao Paulo、ブラジル、04038-031
- Local Institution
-
Sao Paulo、ブラジル、08270-070
- Local Institution
-
Sao Paulo、ブラジル、08270
- Local Institution
-
-
Bahia
-
Salvador、Bahia、ブラジル、40144
- Local Institution
-
Salvador、Bahia、ブラジル、41810
- Local Institution
-
Salvador、Bahia、ブラジル、40144-900
- Local Institution
-
Salvador、Bahia、ブラジル、41810-010
- Local Institution
-
-
Minas Gerais
-
Belo Horzonte、Minas Gerais、ブラジル、30150-221
- Local Institution
-
Belo Horzonte、Minas Gerais、ブラジル、30150
- Local Institution
-
Juiz De Fora、Minas Gerais、ブラジル、36021-630
- Local Institution
-
Juiz De Fora、Minas Gerais、ブラジル、36021
- Local Institution
-
Uberaba、Minas Gerais、ブラジル、38056 055
- Local Institution
-
Uberlandia、Minas Gerais、ブラジル、38400-299
- Local Institution
-
Uberlandia、Minas Gerais、ブラジル、38400
- Local Institution
-
-
Para
-
Belem、Para、ブラジル、66087-660
- Local Institution
-
Belem、Para、ブラジル、66087
- Local Institution
-
-
Parana
-
Campina Grande Do Sul、Parana、ブラジル、83430-000
- Local Institution
-
Campina Grande Do Sul、Parana、ブラジル、83430
- Local Institution
-
Curitiba、Parana、ブラジル、80010
- Local Institution
-
Curitiba、Parana、ブラジル、80730
- Local Institution
-
Curitiba、Parana、ブラジル、80010-030
- Local Institution
-
Curitiba、Parana、ブラジル、80730-150
- Local Institution
-
Londrina、Parana、ブラジル、86010-450
- Local Institution
-
Londrina、Parana、ブラジル、86010
- Local Institution
-
-
RIO Grande DO Norte
-
Natal、RIO Grande DO Norte、ブラジル、59020-100
- Local Institution
-
-
RIO Grande DO SUL
-
Porte Alegre、RIO Grande DO SUL、ブラジル、90610-000
- Local Institution
-
Porte Alegre、RIO Grande DO SUL、ブラジル、90880-480
- Local Institution
-
Porto Alegre、RIO Grande DO SUL、ブラジル、90035-903
- Local Institution
-
Porto Alegre、RIO Grande DO SUL、ブラジル、90020-090
- Local Institution
-
Porto Alegre、RIO Grande DO SUL、ブラジル、90620-001
- Local Institution
-
Porto Alegre、RIO Grande DO SUL、ブラジル、91350-280
- Local Institution
-
-
Rio Grande Do Norte
-
Natal、Rio Grande Do Norte、ブラジル、59020
- Local Institution
-
-
Rio Grande Do Sul
-
Porte Alegre、Rio Grande Do Sul、ブラジル、90610
- Local Institution
-
Porte Alegre、Rio Grande Do Sul、ブラジル、90880480
- Local Institution
-
Porto Alegre、Rio Grande Do Sul、ブラジル、90035
- Local Institution
-
Porto Alegre、Rio Grande Do Sul、ブラジル、90020
- Local Institution
-
Porto Alegre、Rio Grande Do Sul、ブラジル、90620
- Local Institution
-
Porto Alegre、Rio Grande Do Sul、ブラジル、91350
- Local Institution
-
-
SAO Paulo
-
Botucatu、SAO Paulo、ブラジル、18618-000
- Local Institution
-
Campinas、SAO Paulo、ブラジル、13059-740
- Local Institution
-
Marilia、SAO Paulo、ブラジル、17515-000
- Local Institution
-
Marilia、SAO Paulo、ブラジル、17515-460
- Local Institution
-
Marilia、SAO Paulo、ブラジル、17519-000
- Local Institution
-
San Jose Do Rio Preto、SAO Paulo、ブラジル、15090-000
- Local Institution
-
Santo Andre、SAO Paulo、ブラジル、09190-610
- Local Institution
-
Sao Jose Do Rio Preto、SAO Paulo、ブラジル、15015-750
- Local Institution
-
Sao Jose Do Rio Preto、SAO Paulo、ブラジル、15015-210
- Local Institution
-
-
Santa Catarina
-
Blumenau、Santa Catarina、ブラジル、89010
- Local Institution
-
Blumenau、Santa Catarina、ブラジル、89010-500
- Local Institution
-
Sao Jose、Santa Catarina、ブラジル、88103
- Local Institution
-
Sao Jose、Santa Catarina、ブラジル、88103-450
- Local Institution
-
-
Sao Paulo
-
Botucatu、Sao Paulo、ブラジル、18618
- Local Institution
-
Campinas、Sao Paulo、ブラジル、13059
- Local Institution
-
Marilia、Sao Paulo、ブラジル、17519
- Local Institution
-
Marilia、Sao Paulo、ブラジル、17515
- Local Institution
-
San Jose Do Rio Preto、Sao Paulo、ブラジル、15090
- Local Institution
-
Santo Andre、Sao Paulo、ブラジル、09190
- Local Institution
-
Sao Jose Do Rio Preto、Sao Paulo、ブラジル、15015
- Local Institution
-
-
-
-
-
Cayey、プエルトリコ、00736
- Local Institution
-
Cidra、プエルトリコ、00739
- Local Institution
-
Ponce、プエルトリコ、00717
- Local Institution
-
-
-
-
-
Aalst、ベルギー、9300
- Local Institution
-
Antwerpen、ベルギー、2020
- Local Institution
-
Antwerpen、ベルギー、2060
- Local Institution
-
Arlon、ベルギー、6700
- Local Institution
-
Brugge、ベルギー、8000
- Local Institution
-
Brussels、ベルギー、1090
- Local Institution
-
Dillingen、ベルギー、66763
- Local Institution
-
Genk、ベルギー、3600
- Local Institution
-
Gent、ベルギー、9000
- Local Institution
-
Gilly、ベルギー、6060
- Local Institution
-
Hasselt、ベルギー、3500
- Local Institution
-
Huy、ベルギー、4500
- Local Institution
-
Kortrijk、ベルギー、8500
- Local Institution
-
Menen、ベルギー、8930
- Local Institution
-
Mol、ベルギー、2400
- Local Institution
-
Montegnee、ベルギー、4420
- Local Institution
-
Verviers、ベルギー、4800
- Local Institution
-
Woluwe- Saint Lambert、ベルギー、1200
- Local Institution
-
Yvoir、ベルギー、5530
- Local Institution
-
-
-
-
-
Lima、ペルー、LIMA 33
- Local Institution
-
Lima、ペルー、LIMA 01
- Local Institution
-
Lima、ペルー、LIMA 1
- Local Institution
-
-
Callao
-
Bellavista、Callao、ペルー、2176
- Local Institution
-
Bellavista、Callao、ペルー、CALLAO 2
- Local Institution
-
-
Lambayeque
-
Chiclayo、Lambayeque、ペルー、CIX
- Local Institution
-
-
Lima
-
Jesus Maria、Lima、ペルー、11
- Local Institution
-
Jesus Maria、Lima、ペルー、LIMA 11
- Local Institution
-
Miraflores、Lima、ペルー、LIMA 18
- Local Institution
-
San Borja、Lima、ペルー、LIMA 41
- Local Institution
-
San Martin De Porres、Lima、ペルー、LIMA 31
- Local Institution
-
-
-
-
-
Gdynia、ポーランド、81-423
- Local Institution
-
Gdynia、ポーランド、81-472
- Local Institution
-
Gdynia、ポーランド、81-519
- Local Institution
-
Grodzisk Mazowiecki、ポーランド、05-825
- Local Institution
-
Inowroclaw、ポーランド、88-100
- Local Institution
-
Kielce、ポーランド、25-736
- Local Institution
-
Kielce、ポーランド、25-763
- Local Institution
-
Krakow、ポーランド、31-202
- Local Institution
-
Krakow、ポーランド、30-092
- Local Institution
-
Krakow、ポーランド、31-135
- Local Institution
-
Lodz、ポーランド、91-347
- Local Institution
-
Lodz、ポーランド、91347
- Local Institution
-
Piotrkow Trybunalski、ポーランド、97-300
- Local Institution
-
Plock、ポーランド、09-402
- Local Institution
-
Plock、ポーランド、09-400
- Local Institution
-
Plonsk、ポーランド、09-100
- Local Institution
-
Poznan、ポーランド、60-531
- Local Institution
-
Poznan、ポーランド、60479
- Local Institution
-
Ruda Slaska、ポーランド、41-703
- Local Institution
-
Skierniewice、ポーランド、96-100
- Local Institution
-
Slupsk、ポーランド、76-200
- Local Institution
-
Torun、ポーランド、87100
- Local Institution
-
Warszawa、ポーランド、01-138
- Local Institution
-
Warszawa、ポーランド、04-073
- Local Institution
-
Warszawa、ポーランド、04-628
- Local Institution
-
Warszawa、ポーランド、04-749
- Local Institution
-
Wegrow、ポーランド、07100
- Local Institution
-
-
-
-
-
Kuala Lumpur、マレーシア、56000
- Local Institution
-
Kuala Lumpur、マレーシア、59100
- Local Institution
-
-
Kelantan
-
Kubang Kerian、Kelantan、マレーシア、16150
- Local Institution
-
-
Sarawak
-
Kota Samarahan、Sarawak、マレーシア、94300
- Local Institution
-
-
Selangor
-
Batu Caves、Selangor、マレーシア、68100
- Local Institution
-
-
-
-
-
Puebla、メキシコ、11490
- Local Institution
-
Queretaro、メキシコ、76000
- Local Institution
-
-
BAJA California
-
Tijuana、BAJA California、メキシコ、22500
- Local Institution
-
-
Distrito Federal
-
Col. Toriello Guerra、Distrito Federal、メキシコ、CP 14050
- Local Institution
-
Mexico City、Distrito Federal、メキシコ、06726
- Local Institution
-
Mexico City、Distrito Federal、メキシコ、14080
- Local Institution
-
Mexico City、Distrito Federal、メキシコ、07760
- Local Institution
-
Mexico City、Distrito Federal、メキシコ、06070
- Local Institution
-
Mexico City、Distrito Federal、メキシコ、10700
- Local Institution
-
-
Jalisco
-
Guadalajara、Jalisco、メキシコ、44200
- Local Institution
-
Guadalajara、Jalisco、メキシコ、44600
- Local Institution
-
Guadalajara、Jalisco、メキシコ、44656
- Local Institution
-
-
Michoacan
-
Morelia、Michoacan、メキシコ、58000
- Local Institution
-
-
Nuevo LEON
-
Monterrey、Nuevo LEON、メキシコ、64710
- Local Institution
-
Monterrey、Nuevo LEON、メキシコ、64000
- Local Institution
-
Monterrey、Nuevo LEON、メキシコ、64700
- Local Institution
-
-
Sinaloa
-
Culiacan、Sinaloa、メキシコ、80020
- Local Institution
-
-
Veracruz
-
Jalapa、Veracruz、メキシコ、91020
- Local Institution
-
-
-
-
-
Baia Mare、ルーマニア、430031
- Local Institution
-
Bucharest、ルーマニア、011192
- Local Institution
-
Bucharest、ルーマニア、020125
- Local Institution
-
Bucharest、ルーマニア、050098
- Local Institution
-
Bucharest、ルーマニア、021659
- Local Institution
-
Bucharest、ルーマニア、030572
- Local Institution
-
Cluj Napoca、ルーマニア、400001
- Local Institution
-
Cluj Napoca、ルーマニア、400347
- Local Institution
-
Iasi、ルーマニア、700503
- Local Institution
-
Oradea、ルーマニア、410169
- Local Institution
-
Sibiu、ルーマニア、550245
- Local Institution
-
Targu-Mures、ルーマニア、540103
- Local Institution
-
Timisoara、ルーマニア、300024
- Local Institution
-
Timisoara、ルーマニア、300320
- Local Institution
-
Tirgu Mures、ルーマニア、540136
- Local Institution
-
-
-
-
-
Chelyabinsk、ロシア連邦、454136
- Local Institution
-
Chita、ロシア連邦、672090
- Local Institution
-
Dzerzhinskiy、ロシア連邦、140091
- Local Institution
-
Kazan、ロシア連邦、420012
- Local Institution
-
Kemerovo、ロシア連邦、650002
- Local Institution
-
Kirovsk、ロシア連邦、187342
- Local Institution
-
Krasnodar、ロシア連邦、350042
- Local Institution
-
Moscow、ロシア連邦、119992
- Local Institution
-
Moscow、ロシア連邦、125367
- Local Institution
-
Moscow、ロシア連邦、109240
- Local Institution
-
Moscow、ロシア連邦、105229
- Local Institution
-
Moscow、ロシア連邦、111539
- Local Institution
-
Moscow、ロシア連邦、115487
- Local Institution
-
Moscow、ロシア連邦、115093
- Local Institution
-
Moscow、ロシア連邦、121552
- Local Institution
-
Moscow、ロシア連邦、117593
- Local Institution
-
Moscow、ロシア連邦、127018
- Local Institution
-
Moscow、ロシア連邦、125284
- Local Institution
-
Moscow、ロシア連邦、111020
- Local Institution
-
Moscow、ロシア連邦、119121
- Local Institution
-
Moscow、ロシア連邦、121356
- Local Institution
-
Moscow、ロシア連邦、117556
- Local Institution
-
Moscow、ロシア連邦、119048
- Local Institution
-
Moscow、ロシア連邦、123182
- Local Institution
-
Moscow、ロシア連邦、125206
- Local Institution
-
Moscow、ロシア連邦、125424
- Local Institution
-
Moscow、ロシア連邦、129090
- Local Institution
-
Nizhni Novgorod、ロシア連邦、603003
- Local Institution
-
Nizhni Novgorod、ロシア連邦、603005
- Local Institution
-
Novosibirsk、ロシア連邦、630008
- Local Institution
-
Novosibirsk、ロシア連邦、630054
- Local Institution
-
Odintsovo、ロシア連邦、143000
- Local Institution
-
Penza、ロシア連邦、440026
- Local Institution
-
Perm、ロシア連邦、614097
- Local Institution
-
Rostov-On-Don、ロシア連邦、344022
- Local Institution
-
Ryazan、ロシア連邦、390026
- Local Institution
-
Saint Petersburg、ロシア連邦、193312
- Local Institution
-
Saint Petersburg、ロシア連邦、193144
- Local Institution
-
Saint-Petersburg、ロシア連邦、190103
- Local Institution
-
Saint-Petersburg、ロシア連邦、191025
- Local Institution
-
Saint-Petersburg、ロシア連邦、193163
- Local Institution
-
Saint-Petersburg、ロシア連邦、196601
- Local Institution
-
Saint-Petersburg、ロシア連邦、198013
- Local Institution
-
Samara、ロシア連邦、443070
- Local Institution
-
Saratov、ロシア連邦、410002
- Local Institution
-
St Petersburg、ロシア連邦、198013
- Local Institution
-
St Petersburg、ロシア連邦、192288
- Local Institution
-
St-Petersburg、ロシア連邦、194354
- Local Institution
-
St-Petersburg、ロシア連邦、195271
- Local Institution
-
St. Petersburg、ロシア連邦、197341
- Local Institution
-
St. Petersburg、ロシア連邦、197110
- Local Institution
-
St.-Petersburg、ロシア連邦、197341
- Local Institution
-
St.Petersburg、ロシア連邦、199106
- Local Institution
-
Tomsk、ロシア連邦、634012
- Local Institution
-
Tumen、ロシア連邦、625023
- Local Institution
-
Tver、ロシア連邦、170036
- Local Institution
-
Voronezh、ロシア連邦、394066
- Local Institution
-
Voronezh、ロシア連邦、394065
- Local Institution
-
Yaroslavl、ロシア連邦、150030
- Local Institution
-
Yaroslavl、ロシア連邦、150003
- Local Institution
-
Yaroslavl、ロシア連邦、150002
- Local Institution
-
Zheleznodorozhniy、ロシア連邦、143920
- Local Institution
-
Zhukovsky、ロシア連邦、140160
- Local Institution
-
Zhukovsky、ロシア連邦、140180
- Local Institution
-
-
-
-
-
Ankara、七面鳥、06100
- Local Institution
-
Eskisehir、七面鳥、26480
- Local Institution
-
Izmir、七面鳥、35100
- Local Institution
-
-
-
-
Beijing
-
Beijing、Beijing、中国、100050
- Local Institution
-
Beijing、Beijing、中国、100001
- Local Institution
-
Beijing、Beijing、中国、100853
- Local Institution
-
Beijing、Beijing、中国、100020
- Local Institution
-
Beijing、Beijing、中国、100088
- Local Institution
-
Beijing、Beijing、中国、100101
- Local Institution
-
-
Gansu
-
Lanzhou、Gansu、中国、730000
- Local Institution
-
Lanzhou、Gansu、中国、730030
- Local Institution
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510080
- Local Institution
-
Guangzhou、Guangdong、中国、510120
- Local Institution
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050000
- Local Institution
-
-
Heilongjiang
-
Daqing、Heilongjiang、中国、163001
- Local Institution
-
Haerbin、Heilongjiang、中国、150086
- Local Institution
-
Haerbin、Heilongjiang、中国、150001
- Local Institution
-
-
Hubei
-
Wuhan、Hubei、中国、430060
- Local Institution
-
-
Hunan
-
Changsha、Hunan、中国、410000
- Local Institution
-
-
Jiangsu
-
Hangzhou、Jiangsu、中国、310009
- Local Institution
-
Nanjing、Jiangsu、中国、210029
- Local Institution
-
-
Liaoning
-
Dalian、Liaoning、中国、116011
- Local Institution
-
Dalian、Liaoning、中国、116021
- Local Institution
-
Dalian、Liaoning、中国、116027
- Local Institution
-
Shenyang、Liaoning、中国、110016
- Local Institution
-
Shenyang、Liaoning、中国、110003
- Local Institution
-
-
Shandong
-
Jinan、Shandong、中国、250012
- Local Institution
-
Jinan、Shandong、中国、250033
- Local Institution
-
Qingdao、Shandong、中国、266011
- Local Institution
-
-
Shanghai
-
Shanghai、Shanghai、中国、200080
- Local Institution
-
Shanghai、Shanghai、中国、200025
- Local Institution
-
Shanghai、Shanghai、中国、200433
- Local Institution
-
Shanghai、Shanghai、中国、200011
- Local Institution
-
Shanghai、Shanghai、中国、200233
- Local Institution
-
Shanghai、Shanghai、中国、200003
- Local Institution
-
Shanghai、Shanghai、中国、100037
- Local Institution
-
Shanghai、Shanghai、中国、200031
- Local Institution
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- Local Institution
-
Chongqing、Sichuan、中国、400010
- Local Institution
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310009
- Local Institution
-
-
-
-
Bloemfontein
-
Westdene、Bloemfontein、南アフリカ、9301
- Local Institution
-
-
Cape Town
-
Observatory、Cape Town、南アフリカ、7925
- Local Institution
-
-
Gauteng
-
Pretoria、Gauteng、南アフリカ、0084
- Local Institution
-
Pretoria、Gauteng、南アフリカ、0132
- Local Institution
-
-
KWA ZULU Natal
-
Richards Bay、KWA ZULU Natal、南アフリカ、3900
- Local Institution
-
-
Western CAPE
-
Bellville Cape Town、Western CAPE、南アフリカ、7530
- Local Institution
-
George、Western CAPE、南アフリカ、6529
- Local Institution
-
Parow、Western CAPE、南アフリカ、7505
- Local Institution
-
Somerset West、Western CAPE、南アフリカ、7130
- Local Institution
-
Worcester、Western CAPE、南アフリカ、6850
- Local Institution
-
-
-
-
-
Taipei、台湾、100
- Local Institution
-
Taipei、台湾、112
- Local Institution
-
Taipei、台湾、111
- Local Institution
-
Taipei、台湾、220
- Local Institution
-
Taipei、台湾、10449
- Local Institution
-
Taipei、台湾、104
- Local Institution
-
-
-
-
-
Busan、大韓民国、602-702
- Local Institution
-
Daegu、大韓民国、700-712
- Local Institution
-
Daegu、大韓民国、705-717
- Local Institution
-
Daejon、大韓民国、302-718
- Local Institution
-
Goyang、大韓民国、411-706
- Local Institution
-
Gwang Ju、大韓民国、501-757
- Local Institution
-
Gyeonggi、大韓民国、463-707
- Local Institution
-
Pusan、大韓民国、602-739
- Local Institution
-
Scongnam-Si、大韓民国、463-712
- Local Institution
-
Seoul、大韓民国、110-744
- Local Institution
-
Seoul、大韓民国、143-729
- Local Institution
-
Seoul、大韓民国、130-709
- Local Institution
-
Suwon、大韓民国、443-721
- Local Institution
-
-
Gyeonggi-Do
-
Anyang-Si、Gyeonggi-Do、大韓民国、431-070
- Local Institution
-
-
Korea
-
Incheon、Korea、大韓民国、400-711
- Local Institution
-
-
-
-
-
Fukui、日本、9100067
- Local Institution
-
Kagoshima、日本、8920822
- Local Institution
-
Kyoto、日本、6168152
- Local Institution
-
Nagasaki、日本、852-8102
- Local Institution
-
Oita、日本、8700033
- Local Institution
-
Osaka、日本、558-8558
- Local Institution
-
Osaka、日本、551-0032
- Local Institution
-
Osaka、日本、5510032
- Local Institution
-
Saga、日本、8490917
- Local Institution
-
-
Fukuoka
-
Itoshima City、Fukuoka、日本、819-1104
- Local Institution
-
Kurume、Fukuoka、日本、8390863
- Local Institution
-
Ohkawa-City、Fukuoka、日本、8310016
- Local Institution
-
-
Fukushima
-
Shirakawa City、Fukushima、日本、961-0005
- Local Institution
-
-
Gunma
-
Takasaki City、Gunma、日本、3700829
- Local Institution
-
-
Hokkaido
-
Asahikawa-Shi、Hokkaido、日本、0788214
- Local Institution
-
Katou-Gun、Hokkaido、日本、0800111
- Local Institution
-
Katou-gun、Hokkaido、日本、080111
- Local Institution
-
Sapporo-Shi、Hokkaido、日本、0028043
- Local Institution
-
Tomakomai-Shi、Hokkaido、日本、002-8043
- Local Institution
-
Tomakomai-shi、Hokkaido、日本、0028043
- Local Institution
-
Yubari、Hokkaido、日本、0680402
- Local Institution
-
-
Hyogo
-
Kobe、Hyogo、日本、6540026
- Local Institution
-
-
Kagoshima Prefecture
-
Izumi City、Kagoshima Prefecture、日本、8990131
- Local Institution
-
-
Kanagawa
-
Isehara、Kanagawa、日本、2591193
- Local Institution
-
Yokohama、Kanagawa、日本、2458575
- Local Institution
-
Yokohama City、Kanagawa、日本、2278501
- Local Institution
-
Yokosuka、Kanagawa、日本、2388567
- Local Institution
-
-
Miyagi
-
Sendai City、Miyagi、日本、983-8520
- Local Institution
-
-
Nara
-
Nara City、Nara、日本、630-8305
- Local Institution
-
-
Osaka
-
Izumi City、Osaka、日本、594-0071
- Local Institution
-
Osaka City、Osaka、日本、5330022
- Local Institution
-
Osaka-Shi、Osaka、日本、540-0006
- Local Institution
-
Osaka-shi、Osaka、日本、5400006
- Local Institution
-
Suita-City、Osaka、日本、5658565
- Local Institution
-
Takatsuki City、Osaka、日本、5690852
- Local Institution
-
Yao、Osaka、日本、5810036
- Local Institution
-
-
Saga
-
Saga City、Saga、日本、840-8571
- Local Institution
-
Saga City、Saga、日本、849-8501
- Local Institution
-
-
Saitama
-
Kasukabe-Shi、Saitama、日本、344-0035
- Local Institution
-
Kasukabe-shi、Saitama、日本、3440035
- Local Institution
-
-
Tokyo
-
Itabashi-Ku、Tokyo、日本、173-0015
- Local Institution
-
Itabashi-ku、Tokyo、日本、1730015
- Local Institution
-
Meguro-Ku、Tokyo、日本、153-8515
- Local Institution
-
Meguro-ku、Tokyo、日本、1538515
- Local Institution
-
Shinagawa-Ku、Tokyo、日本、1428666
- Local Institution
-
-
Toyama
-
Toyama City、Toyama、日本、9308550
- Local Institution
-
-
Yamaguchi
-
Iwakuni、Yamaguchi、日本、7400021
- Local Institution
-
-
-
-
-
Hong Kong、香港
- Local Institution
-
Shatin、香港
- Local Institution
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:
- Age ≥ 75, previous stroke
- transient ischemic attack (TIA) or Systemic Embolism (SE)
- Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40%
- Diabetes mellitus or hypertension requiring pharmacological treatment
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：2
|
Oral tablets, 5.0 mg or 2.5 mg, twice daily
他の名前：
|
|
アクティブコンパレータ：1
|
Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period
時間枠：Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
|
All suspected efficacy events were adjudicated by the Central Events Committee (CEC).
Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction).
Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
|
Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period
時間枠："Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate=Number of adjudicated stroke or SE events per 100 patient years.
Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction).
Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years.
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Number of Participants With Events of All-Cause Death During the Intended Treatment Period
時間枠："Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Death was defined as all-cause mortality.
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided.
Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths.
Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Adjudicated All-Cause Death During the Intended Treatment Period
時間枠："Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided.
Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths.
Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period
時間枠："Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads.
For descriptions of Stroke and SE, see Outcome Measure 1.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period
時間枠："Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads.
For descriptions of Stroke and SE, see Outcome Measure 1.
For description of ACD, see Outcome Measure 5.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period
時間枠："Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
For descriptions of Stroke and SE, see Outcome Measure 1.
For description of Major bleeding, see Outcome Measure 3.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period
時間枠："Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
|
Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death.
CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of major or CRNM bleed events per 100 patient years.
Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death.
CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Number of Participants With All Bleeding Events During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding.
Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding.
Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of All Bleeding Events During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of all bleeding events per 100 patient years.
"All bleeding events" include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding.
Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding.
Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD).
SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD.
Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD.
Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued.
Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated GUSTO bleeding events per 100 patient years.
GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention.
GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated TIMI bleeding events per 100 patient years.
TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions.
Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Number of Participants With Net-Clinical Benefit During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Net-Clinical Benefit During Treatment Period
時間枠："Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of events of net-clinical benefit per 100 patient years.
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16.
- Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
- Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
- Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
- Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
- Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
- Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582-90. doi: 10.1093/eurheartj/ehw054. Epub 2016 Feb 25.
- Hijazi Z, Granger CB, Hohnloser SH, Westerbergh J, Lindback J, Alexander JH, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Wallentin L. Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. J Am Heart Assoc. 2020 Sep 15;9(18):e017155. doi: 10.1161/JAHA.120.017155. Epub 2020 Aug 31.
- Zeitouni M, Giczewska A, Alexander JH. Reply: Specifics of Dose Modification in ARISTOTLE. J Am Coll Cardiol. 2020 Jul 7;76(1):128-129. doi: 10.1016/j.jacc.2020.05.013. No abstract available.
- Rosjo H, Hijazi Z, Omland T, Westerbergh J, Lyngbakken MN, Alexander JH, Gersh BJ, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. J Intern Med. 2020 Aug;288(2):248-259. doi: 10.1111/joim.13072. Epub 2020 May 18.
- Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH; ARISTOTLE Investigators. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020 Mar 17;75(10):1145-1155. doi: 10.1016/j.jacc.2019.12.060.
- Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020 Apr 28;141(17):1384-1392. doi: 10.1161/CIRCULATIONAHA.119.044059. Epub 2020 Mar 12.
- Garcia DA, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, Granger CB, Held C, Wallentin L, Alexander JH, Lopes RD. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2020 Mar;221:1-8. doi: 10.1016/j.ahj.2019.10.013. Epub 2019 Oct 31.
- Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 Jan 7;141(1):10-20. doi: 10.1161/CIRCULATIONAHA.119.041296. Epub 2019 Nov 21.
- Goldstein SA, Green J, Huber K, Wojdyla DM, Lopes RD, Alexander JH, Vinereanu D, Wallentin L, Granger CB, Al-Khatib SM. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). Am J Cardiol. 2019 Nov 1;124(9):1406-1412. doi: 10.1016/j.amjcard.2019.07.046. Epub 2019 Aug 7.
- Guimaraes PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A, Carnicelli A, Lewis BS, Hanna M, Wallentin L, Vinereanu D, Alexander JH, Granger CB. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9.
- Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019 Apr;47(3):345-352. doi: 10.1007/s11239-019-01823-y.
- Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
- Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 Feb;208:123-131. doi: 10.1016/j.ahj.2018.09.017. Epub 2018 Nov 22.
- Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L. Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart. 2018 Nov 1;5(2):e000908. doi: 10.1136/openhrt-2018-000908. eCollection 2018.
- Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019 Feb;105(3):235-242. doi: 10.1136/heartjnl-2018-313351. Epub 2018 Sep 12.
- Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L; ARISTOTLE Investigators. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018 Aug 14;72(7):721-733. doi: 10.1016/j.jacc.2018.05.058.
- Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125.
- Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, Verheugt FWA, Vinereanu D, Bahit MC, Halvorsen S, Huber K, Parkhomenko A, Granger CB, Lopes RD, Alexander JH. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J. 2018 Mar;197:133-141. doi: 10.1016/j.ahj.2017.11.005. Epub 2017 Nov 10.
- Pol T, Held C, Westerbergh J, Lindback J, Alexander JH, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018 Feb 1;7(3):e007444. doi: 10.1161/JAHA.117.007444.
- Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola VP, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, Alexander JH. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):75-81. doi: 10.1093/ehjcvp/pvy002.
- Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, Gersh BJ, Avezum A, Hanna M, Held C, Wallentin L, Granger CB, Alexander JH. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018 Aug;104(15):1292-1299. doi: 10.1136/heartjnl-2017-312272. Epub 2018 Jan 19.
- Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB; Apixaban for Reduction in Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018 Mar;131(3):269-275.e2. doi: 10.1016/j.amjmed.2017.10.036. Epub 2017 Nov 6.
- Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D, Wallentin L, Granger CB, Alexander JH; ARISTOTLE Investigators. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017 Dec;48(12):3266-3273. doi: 10.1161/STROKEAHA.117.017574. Epub 2017 Oct 31.
- Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindback J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23;6(6):e004851. doi: 10.1161/JAHA.116.004851.
- Lopes RD, Guimaraes PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de Barros E Silva P, Alexander JH, Granger CB, Diener HC. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017 Jun 1;129(22):2980-2987. doi: 10.1182/blood-2016-08-731638. Epub 2017 Mar 29.
- Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017 May 1;2(5):525-534. doi: 10.1001/jamacardio.2017.0065.
- Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17;6(1):e004699. doi: 10.1161/JAHA.116.004699.
- Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017 Apr;103(8):623-628. doi: 10.1136/heartjnl-2016-309901. Epub 2016 Oct 24.
- Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 Sep 1;1(6):673-81. doi: 10.1001/jamacardio.2016.1829.
- Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016 Jul 1;1(4):451-60. doi: 10.1001/jamacardio.2016.1170.
- Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016 Jun 15;353:i2868. doi: 10.1136/bmj.i2868.
- Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L; ARISTOTLE Investigators. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr;102(7):508-17. doi: 10.1136/heartjnl-2015-308887. Epub 2016 Feb 2.
- Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec 1;4(12):e002015. doi: 10.1161/JAHA.115.002015. Erratum In: J Am Heart Assoc. 2021 Feb 16;10(4):e014653.
- Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7;36(46):3268-75. doi: 10.1093/eurheartj/ehv447. Epub 2015 Sep 14.
- Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807. Epub 2015 Jun 23.
- Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21;36(20):1264-72. doi: 10.1093/eurheartj/ehu463. Epub 2014 Dec 12.
- Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015 Feb;61(2):368-78. doi: 10.1373/clinchem.2014.226936. Epub 2014 Dec 1.
- Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11;124(25):3692-8. doi: 10.1182/blood-2014-08-595496. Epub 2014 Oct 15.
- Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A; ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18;130(21):1847-58. doi: 10.1161/CIRCULATIONAHA.114.011204. Epub 2014 Oct 7.
- Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L; ARISTOTLE Investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11;129(6):625-34. doi: 10.1161/CIRCULATIONAHA.113.006286. Epub 2013 Nov 13.
- Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63(11):1082-7. doi: 10.1016/j.jacc.2013.09.062. Epub 2013 Nov 6.
- Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB; ARISTOTLE Investigators. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014 Jan 7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093. Epub 2013 Sep 19.
- Alexander JH, Levy E, Lawrence J, Hanna M, Waclawski AP, Wang J, Califf RM, Wallentin L, Granger CB. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. Am Heart J. 2013 Sep;166(3):559-65. doi: 10.1016/j.ahj.2013.05.025. Epub 2013 Aug 15.
- Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25.
- Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4;127(22):2166-76. doi: 10.1161/CIRCULATIONAHA.112.142158. Epub 2013 May 2.
- McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M, Alexander JH, Lopes RD, Wojdyla DM, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013 May;6(3):451-60. doi: 10.1161/CIRCHEARTFAILURE.112.000143. Epub 2013 Apr 10.
- Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082. Epub 2013 Apr 3.
- Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Erratum In: Lancet. 2013 Jan 19;381(9862):204.
- Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum In: Lancet Neurol. 2012 Dec;11(12):1021.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2006年12月31日
一次修了 (実際)
2011年5月25日
研究の完了 (実際)
2011年5月25日
試験登録日
最初に提出
2006年12月18日
QC基準を満たした最初の提出物
2006年12月18日
最初の投稿 (見積もり)
2006年12月19日
学習記録の更新
投稿された最後の更新 (実際)
2018年7月3日
QC基準を満たした最後の更新が送信されました
2018年6月5日
最終確認日
2018年5月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。